Compounding HRT Solutions for Integrative Hormone Wellness Patients

According to NAMS (The Menopause Society) and the ACOG Practice Bulletin on menopause, hot flashes in the context of declining estrogen levels may present as sudden intense waves of heat, commonly beginning in the face, neck, and chest, and may be accompanied by visible flushing, rapid heartbeat, and profuse sweating. Episodes may last several minutes and may recur during the day or night, with nighttime occurrences often described as night sweats that interrupt sleep. According to the Endocrine Society Clinical Practice Guideline, these vasomotor symptoms reflect altered hypothalamic thermoregulation associated with falling estrogen levels. Patients experiencing frequent or severe hot flashes that significantly disrupt daily functioning or sleep should seek evaluation from a qualified clinician.

According to NAMS (The Menopause Society) and ACOG, night sweats in the context of hormonal changes during perimenopause and menopause may present as episodes of intense perspiration during sleep that may soak clothing or bedding and interrupt sleep continuity. According to the Endocrine Society Clinical Practice Guideline, these nocturnal vasomotor events are closely related to hot flashes and similarly reflect hypothalamic thermoregulatory changes associated with declining estrogen. Persistent sleep disruption due to night sweats may contribute to daytime fatigue, mood disturbance, and reduced cognitive function. Patients experiencing severe or persistent nighttime symptoms should seek evaluation from a qualified clinician.

According to NAMS (The Menopause Society) and ACOG, mood changes associated with perimenopause and menopause may present as sudden or unpredictable emotional shifts, including tearfulness, irritability, heightened anxiety, low motivation, or brief periods of agitation. According to the Endocrine Society Clinical Practice Guideline, these changes are thought to reflect hormonal fluctuations involving estrogen and progesterone, which influence neurotransmitter systems associated with mood regulation. Cognitive symptoms such as difficulty concentrating and indecision may accompany mood instability. These changes may vary in intensity and duration and may arise without an identifiable external trigger. Patients experiencing significant mood disturbance or symptoms suggestive of depression should seek evaluation from a qualified clinician; symptoms that interfere substantially with daily functioning may indicate a need for prompt clinical assessment.

According to NAMS (The Menopause Society) and ACOG, vaginal dryness in the context of menopause — often described as part of the genitourinary syndrome of menopause (GSM) — may present as persistent decreased moisture and lubrication, with thinning and fragility of vaginal mucosa. According to the FDA-approved prescribing information for DHEA (prasterone) vaginal insert, symptoms of vulvar and vaginal atrophy may include dryness, itching, burning, and pain with sexual activity. The vaginal tissue may appear pale and less elastic, and patients may notice increased sensitivity, discomfort with penetration, and recurrent irritation. Patients experiencing significant vaginal symptoms should seek evaluation from a qualified clinician; symptoms accompanied by unusual discharge, bleeding, or signs of infection may indicate conditions requiring prompt medical assessment.

According to the FDA-approved prescribing information for Estradiol transdermal patch, the estradiol transdermal patch is a transdermal estrogen indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause, and for the prevention of postmenopausal osteoporosis. The labeling describes that the patch delivers 17β-estradiol continuously through the skin, providing relatively steady systemic estradiol levels while minimizing first-pass hepatic metabolism. Per the labeling, estrogen therapy may increase the risk of endometrial cancer in women with a uterus who do not use concomitant progestogen; the labeling includes a boxed warning stating that estrogens increase the risk of endometrial cancer, and that estrogens with or without progestins should not be used for the prevention of cardiovascular disease or dementia. The labeling further states that the use of estrogens may increase the risk of stroke, deep vein thrombosis, pulmonary embolism, and myocardial infarction. Any compounded preparation involving estradiol is not reviewed by FDA for safety or effectiveness before dispensing. Commercially available estradiol transdermal products are separately regulated, and clinical decisions belong with the prescribing clinician.

According to the FDA-approved prescribing information for DHEA (prasterone) vaginal insert, the DHEA (prasterone) vaginal insert is a steroid precursor indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause. The labeling describes that prasterone (dehydroepiandrosterone) is administered intravaginally and is locally converted by vaginal cells to both estrogens and androgens, which may restore vaginal epithelial tissue, improve lubrication, and reduce dyspareunia. Per the labeling, prasterone may result in increases in serum levels of certain sex steroids, and patients receiving hormone-sensitive therapies should consult their prescribing clinician. Any compounded preparation involving DHEA (prasterone) is not reviewed by FDA for safety or effectiveness before dispensing. Commercially available DHEA (prasterone) vaginal insert products are separately regulated, and clinical decisions belong with the prescribing clinician.